Life Valve Project (FP7)

Size: px

Start display at page:

Download "Life Valve Project (FP7)"

Louisa Dixon
6 years ago
Views:

1 Life Valve Project (FP7) Prof. Dr. Dr. Simon P. Hoerstrup University and University Hospital Zurich; Switzerland Cardiovascular Surgery Research / Regenerative Medicine Center 1

2 LifeValve - Living autologous heart valves for minimally invasive implantation procedures 2

3 Regenerative Medicine Paradigm CELLS SCAFFOLD IN VITRO IMPLANT CULTURE AUTOGENIC NATURAL STATIC ALLOGENIC SYNTHETIC DYNAMIC XENOGENIC BIODEGRADABLE 3

4 Cardiovascular Tissue Engineering 4

5 Cardiovascular Tissue Engineering BLOOD VESSELS HEART VALVES MYOCARDIUM 5

6 Current Heart Valve Substitutes DEGENERATION NON-LIVING FOREIGN MATERIALS MEDICATION 6

7 Heart Valve Tissue Engineering CELLS SCAFFOLD IN VITRO IMPLANT CULTURE 7

8 TissueEngineeredHeartValve * HOERSTRUP SP et al. (2000) CIRCULATION 102(III);

9 Proof of Principle In vitro generation of autologous, living and functional heart valves is feasible The tissue engineered valves approximated native heart valves as to morphological and biomechanical features novel, biodegradable scaffold material biomimetic in vitro culture conditions 9

10 Human Applications CELLS SCAFFOLD IN VITRO IMPLANT CULTURE AUTOGENIC SYNTHETIC BIOMIMETIC BIODEGRADABLE 10

(2002) ANNALS THOR SURG 74(4);S1422-8 * KADNER A, HOERSTRUP SP et al. (2004) EJCTS 25(4);635-641 * HOERSTRUP SP et al.

11 Stem Cell-based Heart Valves Differentiated (Vascular Derived) Cells * HOERSTRUP SP et al. (2000) CIRCULATION 102(III);44-49 * HOERSTRUP SP et al. (2006) CIRCULATION 114(I); * MOL A, HOERSTRUP SP et al (2006) CIRCULATION 114 (I) Mesenchymal Progenitor Cells * KADNER A, HOERSTRUP SP et al. (2002) ANNALS THOR SURG 74(4);S * KADNER A, HOERSTRUP SP et al. (2004) EJCTS 25(4); * HOERSTRUP SP et al. (2002) CIRCULATION 106(I); Blood Derived Progenitor Cells * SCHMIDT D, HOERSTRUP SP et al. (2004) AHA * SCHMIDT D, HOERSTRUP SP et al. (2004) ANNALS THOR SURG 78; * SCHMIDT D, HOERSTRUP SP et al (2006) ANNALS THOR SURG 82(4); * SCHMIDT D, HOERSTRUP SP et al. (2006) TISSUE ENGINEERING Prenatal (Placental, Umbilical Blood) Progenitor Cells * SCHMIDT D, HOERSTRUP SP et al. (2005) EJCTS 27(5); * SCHMIDT D, HOERSTRUP SP et al. (2006) CIRCULATION 114(I); * SCHMIDT D, HOERSTRUP SP et al. (2007) CIRCULATION 116(11), I

12 Stem Cells from Human Bone Marrow * HOERSTRUP SP et al. (2002) CIRCULATION 106(I);

13 Children born with Heart Malformation CELLS SCAFFOLD IN VITRO IMPLANT CULTURE 13

14 Prenatal Fetal Stem Cells amniotic fluid fetal stem cells * SCHMIDT D et al. (2007) 14

15 Placental Fetal Stem Cells * SCHMIDT D, HOERSTRUP SP, et al. (2006) CIRCULATION 114(I); * SCHMIDT D, HOERSTRUP SP, et al. (2007) CIRCULATION 116(11):I

16 Aim of the LifeValve project To combine tissue engineering and minimally invasive implantation technology for the benefit of children with congenital heart disease Objectives: Development of a biodegradable scaffold and stent system In vitro creation of autologous cell based living, valve substitutes by tissue engineering methods Minimally invasive implantation technology (nonsurgical) of LifeValve 16

17 Overview - LifeValve Project Biodegradable, self-expanding stent Autologous TE Heart Valve Implantation of LifeValve by minimal invasive implantation technology Production of LifeValve Loading of the LifeValve into an application system In vitro conditioning of LifeValve 17

18 LifeValve - Living autologous heart valves for minimally invasive implantation procedures 18

19 Consortium partners Beneficiary Number Beneficiary name Short name Country 1 (coordinator) University of Zurich (University Hospital) UZH Switzerland 2 Deutsches Herzzentrum Berlin und Charité Universitätsmedizin Berlin DHZB Germany 3 Eindhoven University of Technology TU/e The Netherlands 4 Medical University of Vienna MUW Austria 5 pfm Produkte für die Medizin AG PFM Germany 6 Xeltis AG Xeltis Switzerland 7 QTIS/e QTIS The Netherlands 8 University of Debrecen UDEB Hungary 19

1) Determining the best cell sources and scaffold materials for TEHV development.

1) Determining the best cell sources and scaffold materials for TEHV development. Broadly speaking, my primary research interests focus on the development and application of methodologies that can be employed in the basic understanding and optimization of tissue engineered heart valves